SCHEMBL6626544

SCHEMBL6626544

CCc1ccncc1C(N)=S

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.46
SIRT3 Q9NTG7 1/20 0.46
CYP2A6 P11509 4/20 0.44
CYP2E1 P05181 3/20 0.42
CYP2C8 P10632 3/20 0.42
CYP2D6 P10635 3/20 0.42
CYP2B6 P20813 3/20 0.42
CYP2C19 P33261 3/20 0.42
CYP1A2 P05177 3/20 0.39
CYP2C9 P11712 2/20 0.39
CYP3A4 P08684 1/20 0.39
POLB P06746 1/20 0.39
AOC1 P19801 5/20 0.38
AOC3 Q16853 5/20 0.38
BAZ2B Q9UIF8 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
LOXL2 Q9Y4K0 1/20 0.36
CDC7 O00311 1/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6627688 0.86 CYP2A6 (0.45) TDP1SIRT3CYP2A6CYP2E1CYP2C8
SCHEMBL30990565 0.85 CYP2A6 (0.44) TDP1SIRT3CYP2A6CYP2E1CYP2C8
SCHEMBL9002466 0.83 SIRT3 (0.61) TDP1SIRT3CYP2A6CYP2E1CYP2C8
SCHEMBL123203 0.77 KDM4C (0.51) TDP1SIRT3CYP2A6CYP2E1CYP2C8
SCHEMBL30465694 0.77 KDM4C (0.51) TDP1SIRT3CYP2A6CYP2E1CYP2C8
SCHEMBL3818724 0.77 TDP1 (0.44) TDP1SIRT3CYP2A6CYP2E1CYP2C8
SCHEMBL28859980 0.76 KDM4E (0.48) TDP1SIRT3CYP2A6CYP2E1CYP2C8
SCHEMBL28091219 0.75 CYP3A4 (0.42) TDP1SIRT3CYP2A6CYP2E1CYP2C8
SCHEMBL3816767 0.75 TDP1 (0.66) TDP1SIRT3CYP2A6CYP2E1CYP2C8
Acetic Acid SCHEMBL16666943 0.74 KDM4C (0.49) TDP1SIRT3CYP2A6CYP2E1CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040267017-A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-12-30 US disclosed
EP-1432706-A2 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS Bayer Pharmaceuticals Corporation (US) 2004-06-30 EP disclosed
WO-2003027085-A2 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040267017-A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors CYP17A1, CYP21A2, HSD17B1 TDP1 695/4885SIRT3 1031/4885CYP2A6 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.